BioWisdom joins MDL® Isentris® Alliance

Agreement adds valuable SRS biology data to life sciences content available in MDL® Isentris® system

San Ramon, CA and Cambridge, UK — May 21, 2007 — Elsevier MDL and BioWisdom Ltd. have formed a strategic alliance to connect the MDL® Isentris® discovery informatics system with BioWisdom’s Healthcare Intelligence platform. The first development under this agreement will make BioWisdom’s SRS life sciences information platform accessible via Isentris.

"This agreement brings together the industry standards in biological and chemical data management," said Gordon Baxter, CEO of BioWisdom. "The cross-connection of MDL and BioWisdom software and content supports BioWisdom’s strategy to provide the end user with the fullest possible insight and analysis, ultimately leading to better decision making. We look forward to further combinations of products, as we continue to enhance our software offering to customers."

"Integrating the wide variety of biology data in BioWisdom’s SRS system with the structured chemical data already available in MDL Isentris is a major step in bringing together valuable, multi-disciplinary information for life sciences researchers," said Lars Barfod, President and CEO of Elsevier MDL. "The addition of the important SRS system is a key milestone in making Isentris the platform of choice for integrating critical information across the entire life sciences domain."

BioWisdom’s integrated set of software products includes OmniViz, Sofia and SRS. These tools exploit ontology-based Intelligence Networks on an enterprise scale, enabling discovery and development scientists to build, analyze and visualize semantically normalized knowledge bases derived from hundreds of different information sources. BioWisdom’s SRS platform is the industry standard for providing fast access to diverse life sciences information including genetic, protein, expression, pathway, molecular and clinical data from public and proprietary sources.

As a strategic partner in the MDL® Isentris®Alliance, BioWisdom will work with Elsevier MDL to create connections between these life sciences information tools and MDL solutions. The recently released MDL Isentris 2.0 system integrates information and applications into workflows, providing a research environment where scientists can access internal and external data on demand, collaborate with colleagues, analyze data and gain insight to make informed decisions. Along with significant new features and performance improvements, the new release includes .NET controls for rapidly developing and extending custom applications.

BioWisdom joins leading software and consulting companies around the world (including ACD/Labs, DeltaSoft, Eidogen Sertanty, InfoChem, InforSense, Klee, Osthus GmbH, Spotfire, Symyx and Tripos) that are working with Elsevier MDL to create specialized informatics solutions that combine MDL Isentris technology with offerings from different vendors to improve scientific research productivity and return on R&D investment.

###

About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

About BioWisdom
BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the acquisition, integration, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development. BioWisdom's core technologies are its Sofia suite of Intelligence Network tools, its SRS biological data integration platform, its OmniViz visualization software and its proprietary methodologies. For more information, visit www.biowisdom.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Jean Holt
Elsevier MDL
Phone: +1 (925) 543-5400
j.holt@mdl.com